Literature DB >> 15586238

Clinical and biological characteristics of clear cell carcinomas of the ovary in FIGO stages I-II.

Ingirídur Skírnisdóttir1, Tomas Seidal, Mats G Karlsson, Bengt Sorbe.   

Abstract

Clear cell carcinoma of the ovary is considered to be a specific subtype among the epithelial ovarian malignancies. To characterize clear cell carcinomas in early FIGO stages (I-II) with regard to clinical and biological properties, a retrospective study was performed to compare these tumors with other histological subtypes. From a complete series of 226 patients with epithelial ovarian carcinomas in FIGO stages I-II, 28 patients with clear cell carcinomas were selected and the clinical and biological characteristics of these tumors were compared with the remaining non-clear cell carcinomas. All patients underwent primary staging laparotomy followed by adjuvant radiotherapy or chemotherapy. The apoptosis regulators p53, bcl-2 and bax, and the growth factor receptors EGFR and HER-2/neu were analyzed by immunohistochemical techniques and DNA analysis was performed by flow cytometry. Clear cell carcinomas stained negative for p53 significantly more often than other histological subtypes. Positive EGFR staining was seen more frequently in serous carcinomas than in the clear cell carcinomas. Aneuploid DNA status was seen more frequently in clear cell carcinomas than in other histological subtypes and tetraploid tumors made up 50% of the non-diploid tumors. Clear cell tumors were frequently (64%) found in FIGO stages IC and IIC and this was more common than for non-clear cell tumors. No difference was found in the rate of tumor recurrences or survival for patients with clear cell and non-clear cell carcinomas. Clear cell carcinomas of the ovary should be regarded as a separate entity among the epithelial ovarian carcinomas and they differ with regard to both clinical and biological characteristics when compared with non-clear cell tumors.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15586238

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  12 in total

1.  Epigenetic determinants of ovarian clear cell carcinoma biology.

Authors:  Ken Yamaguchi; Zhiqing Huang; Noriomi Matsumura; Masaki Mandai; Takako Okamoto; Tsukasa Baba; Ikuo Konishi; Andrew Berchuck; Susan K Murphy
Journal:  Int J Cancer       Date:  2014-01-14       Impact factor: 7.396

2.  Transcriptional upregulation of HNF-1β by NF-κB in ovarian clear cell carcinoma modulates susceptibility to apoptosis through alteration in bcl-2 expression.

Authors:  Erina Suzuki; Sabine Kajita; Hiroyuki Takahashi; Toshihide Matsumoto; Tomoko Tsuruta; Makoto Saegusa
Journal:  Lab Invest       Date:  2015-06-01       Impact factor: 5.662

Review 3.  Ovarian clear cell adenocarcinoma: a continuing enigma.

Authors:  David S P Tan; Stan Kaye
Journal:  J Clin Pathol       Date:  2006-10-03       Impact factor: 3.411

Review 4.  EGFR/HER-targeted therapeutics in ovarian cancer.

Authors:  Jason A Wilken; Tayf Badri; Sarah Cross; Rhoda Raji; Alessandro D Santin; Peter Schwartz; Adam J Branscum; Andre T Baron; Adam I Sakhitab; Nita J Maihle
Journal:  Future Med Chem       Date:  2012-03       Impact factor: 3.808

5.  Two cases of recurrent ovarian clear cell carcinoma treated with sorafenib.

Authors:  Masafumi Koshiyama; Noriomi Matsumura; Tsukasa Baba; Ken Yamaguchi; Yumiko Yoshioka; Ikuo Konishi
Journal:  Cancer Biol Ther       Date:  2013-10-21       Impact factor: 4.742

6.  Ovarian clear cell carcinoma, outcomes by stage: the MSK experience.

Authors:  Catherine A Shu; Qin Zhou; Anjali R Jotwani; Alexia Iasonos; Mario M Leitao; Jason A Konner; Carol A Aghajanian
Journal:  Gynecol Oncol       Date:  2015-09-25       Impact factor: 5.482

7.  Epigenome-wide ovarian cancer analysis identifies a methylation profile differentiating clear-cell histology with epigenetic silencing of the HERG K+ channel.

Authors:  Mine S Cicek; Devin C Koestler; Brooke L Fridley; Kimberly R Kalli; Sebastian M Armasu; Melissa C Larson; Chen Wang; Stacey J Winham; Robert A Vierkant; David N Rider; Matthew S Block; Brandy Klotzle; Gottfried Konecny; Boris J Winterhoff; Habib Hamidi; Viji Shridhar; Jian-Bing Fan; Daniel W Visscher; Janet E Olson; Lynn C Hartmann; Marina Bibikova; Jeremy Chien; Julie M Cunningham; Ellen L Goode
Journal:  Hum Mol Genet       Date:  2013-04-09       Impact factor: 6.150

Review 8.  Ovarian cancer: pathology, biology, and disease models.

Authors:  Daniel G Rosen; Gong Yang; Guangzhi Liu; Imelda Mercado-Uribe; Bin Chang; Xue Sherry Xiao; Jingfang Zheng; Feng-Xia Xue; Jinsong Liu
Journal:  Front Biosci (Landmark Ed)       Date:  2009-01-01

Review 9.  New perspectives on molecular targeted therapy in ovarian clear cell carcinoma.

Authors:  D S P Tan; R E Miller; S B Kaye
Journal:  Br J Cancer       Date:  2013-04-04       Impact factor: 7.640

10.  Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer.

Authors:  Hui Shen; Brooke L Fridley; Honglin Song; Kate Lawrenson; Julie M Cunningham; Susan J Ramus; Mine S Cicek; Jonathan Tyrer; Douglas Stram; Melissa C Larson; Martin Köbel; Argyrios Ziogas; Wei Zheng; Hannah P Yang; Anna H Wu; Eva L Wozniak; Yin Ling Woo; Boris Winterhoff; Elisabeth Wik; Alice S Whittemore; Nicolas Wentzensen; Rachel Palmieri Weber; Allison F Vitonis; Daniel Vincent; Robert A Vierkant; Ignace Vergote; David Van Den Berg; Anne M Van Altena; Shelley S Tworoger; Pamela J Thompson; Daniel C Tessier; Kathryn L Terry; Soo-Hwang Teo; Claire Templeman; Daniel O Stram; Melissa C Southey; Weiva Sieh; Nadeem Siddiqui; Yurii B Shvetsov; Xiao-Ou Shu; Viji Shridhar; Shan Wang-Gohrke; Gianluca Severi; Ira Schwaab; Helga B Salvesen; Iwona K Rzepecka; Ingo B Runnebaum; Mary Anne Rossing; Lorna Rodriguez-Rodriguez; Harvey A Risch; Stefan P Renner; Elizabeth M Poole; Malcolm C Pike; Catherine M Phelan; Liisa M Pelttari; Tanja Pejovic; James Paul; Irene Orlow; Siti Zawiah Omar; Sara H Olson; Kunle Odunsi; Stefan Nickels; Heli Nevanlinna; Roberta B Ness; Steven A Narod; Toru Nakanishi; Kirsten B Moysich; Alvaro N A Monteiro; Joanna Moes-Sosnowska; Francesmary Modugno; Usha Menon; John R McLaughlin; Valerie McGuire; Keitaro Matsuo; Noor Azmi Mat Adenan; Leon F A G Massuger; Galina Lurie; Lene Lundvall; Jan Lubiński; Jolanta Lissowska; Douglas A Levine; Arto Leminen; Alice W Lee; Nhu D Le; Sandrina Lambrechts; Diether Lambrechts; Jolanta Kupryjanczyk; Camilla Krakstad; Gottfried E Konecny; Susanne Krüger Kjaer; Lambertus A Kiemeney; Linda E Kelemen; Gary L Keeney; Beth Y Karlan; Rod Karevan; Kimberly R Kalli; Hiroaki Kajiyama; Bu-Tian Ji; Allan Jensen; Anna Jakubowska; Edwin Iversen; Satoyo Hosono; Claus K Høgdall; Estrid Høgdall; Maureen Hoatlin; Peter Hillemanns; Florian Heitz; Rebecca Hein; Philipp Harter; Mari K Halle; Per Hall; Jacek Gronwald; Martin Gore; Marc T Goodman; Graham G Giles; Aleksandra Gentry-Maharaj; Montserrat Garcia-Closas; James M Flanagan; Peter A Fasching; Arif B Ekici; Robert Edwards; Diana Eccles; Douglas F Easton; Matthias Dürst; Andreas du Bois; Thilo Dörk; Jennifer A Doherty; Evelyn Despierre; Agnieszka Dansonka-Mieszkowska; Cezary Cybulski; Daniel W Cramer; Linda S Cook; Xiaoqing Chen; Bridget Charbonneau; Jenny Chang-Claude; Ian Campbell; Ralf Butzow; Clareann H Bunker; Doerthe Brueggmann; Robert Brown; Angela Brooks-Wilson; Louise A Brinton; Natalia Bogdanova; Matthew S Block; Elizabeth Benjamin; Jonathan Beesley; Matthias W Beckmann; Elisa V Bandera; Laura Baglietto; François Bacot; Sebastian M Armasu; Natalia Antonenkova; Hoda Anton-Culver; Katja K Aben; Dong Liang; Xifeng Wu; Karen Lu; Michelle A T Hildebrandt; Joellen M Schildkraut; Thomas A Sellers; David Huntsman; Andrew Berchuck; Georgia Chenevix-Trench; Simon A Gayther; Paul D P Pharoah; Peter W Laird; Ellen L Goode; Celeste Leigh Pearce
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.